Patents by Inventor Lars Skriver

Lars Skriver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LIQUID FORMULATION OF GM-CSF FOR INHALATION
    Publication number: 20230201307
    Abstract: Provided here is a liquid formulation comprising recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) for inhalation by nebulization.
    Type: Application
    Filed: March 17, 2021
    Publication date: June 29, 2023
    Inventors: Lars Skriver, Alan Watts
  • Pharmaceutical formulation
    Patent number: 5849700
    Abstract: A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 15, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard
  • Pharmaceutical formulation
    Patent number: 5849704
    Abstract: A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 15, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard
  • Human AlaGlu-IGF-1
    Patent number: 5708134
    Abstract: This invention is directed to isolated human AlaGlu-IGF-1, a novel compound which exerts IGF-1 activity and is a valuable precursor in the preparation of IGF-1 itself.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: January 13, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Lars Skriver, Kim Ry Hejn.ae butted.s, Henrik Dalb.o slashed.ge
  • DNA sequences encoding AlaGlu-IGF-1 and vectors and microorganisms comprising said sequences
    Patent number: 5691168
    Abstract: This invention is directed to isolated DNA sequences encoding AlaGlu-IGF-1, as well as vectors and microorganisms comprising such sequences.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 25, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Lars Skriver, Kim Ry Hejn.ae butted.s, Henrik Dalb.o slashed.ge
  • Method of producing IGF-1
    Patent number: 5459052
    Abstract: Ala-Glu-IGF-I is a novel compound which exerts IGF-I activity and is a precursor for the preparation of IGF-I. Ala-Glu-IGF-I may by converted to IGF-I by renaturation after recombinant production in E. coli under specified conditions and then cleaving Ala-Glu from the IGF-I.
    Type: Grant
    Filed: July 2, 1993
    Date of Patent: October 17, 1995
    Assignee: Novo Nordisk A/S
    Inventors: Lars Skriver, Kim R. Hejn s, Henrik Dalboge